Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH.
- Trial name
- LIGHTRAY EXT (NCT06925750)
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Acute Exposure to High Altitude on Blood and Tissue Oxygenation (ABGA, NIRS)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on blood and tissue oxygenation (ABGA, NIRS).
- Trial name
- NCT03600415
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude, Healthy Adult
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Healthy Adult, Echocardiography, Pulmonary Resistance
- Trial name
- NCT07804485
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
Hemodynamic Response After Six Months of Sildenafil
The purpose of this study is to determine the clinical, functional and hemodynamic response after six months of sildenafil 50 mg TID in patients with pulmonary arterial hypertension.
- Trial name
- NCT00483626
- Testing
- oral sildenafil
- Where
- Chile
- Volunteers
- 27 people
- Sponsor
- University of Chile
Pulmonary Arterial Hypertension, Erectile Dysfunction
A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects
To evaluate the effect of renal insufficiency on the pharmacokinetics of TPN171H tablets after single dose oral administration, so as to provide basis for formulating clinical medication plan for patients with renal…
- Trial name
- NCT05208814
- Testing
- TPN171H single dose
- Where
- 2 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
Coenzyme Q-10 and Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension.
- Trial name
- NCT01148836
- Testing
- Coenzyme Q-10 in Pulmonary Hypertension subjects, Coenzyme Q-10 in Normal Control subjects
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other…
- Trial name
- NCT05224531
- Testing
- CS1 Administration
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Cereno Scientific AB
Idiopathic Pulmonary Arterial Hypertension
Beta-blockers in i-PAH
The main question of this study is: 'Is selective beta-blocker treatment safe and effective in reducing sympathetic overdrive, thereby improving RV function and remodeling in patients with iPAH?'.
- Trial name
- NCT01246037
- Testing
- Bisoprolol
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Hypertension
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV).
- Trial name
- NCT00034307
- Testing
- sitaxsentan sodium
- Where
- 26 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- ICOS-Texas Biotechnology
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
The purpose of this study is: To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT04994119
- Testing
- BIA 5-1058, Warfarin
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Hypertension Outcome Assessment
Zürich Pulmonary Hypertension Outcome Assessment Cohort
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of PH.
- Trial name
- ZHPHCohort (NCT02249806)
- Testing
- PH target therapy according to physician
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Systemic Sclerosis
Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis
Aim: Determination of frequency and nature of coronary involvement (including epicardial and microvascular) among scleroderma patients referred for right heart catheterization.
- Trial name
- NCT00843102
- Where
- Hungary
- Volunteers
- 120 people
- Sponsor
- University of Pecs
Pulmonary Arterial Hypertension
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
- Trial name
- MAESTRO (NCT01743001)
- Testing
- Macitentan 10 mg
- Where
- 55 sites in United States, Austria and 19 more
- Volunteers
- 226 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers
This study is a single-centre, randomized, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability and PK of GMA301 Injection in healthy subjects.
- Trial name
- NCT04505137
- Testing
- GMA301 Injection
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Gmax Biopharm Australia Pty Ltd.
Hypertension, Pulmonary
Pulmonary Hypertension: Assessment of Cell Therapy
The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.
- Trial name
- PHACeT (NCT00469027)
- Testing
- eNOS transfected EPCs will be delivered via a PA line
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Northern Therapeutics
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Trial name
- NCT00625469
- Testing
- bosentan
- Where
- 2 sites in United States
- Sponsor
- Rajan Saggar
Hypertension, Pulmonary
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy.
- Trial name
- NCT00458042
- Testing
- treprostinil sodium
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
- Trial name
- NCT05427162
- Testing
- Prostacyclin Receptor Agonist
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Actelion